|
|
|
Volumn 124, Issue , 2013, Pages 174-190
|
|
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIINFLAMMATORY AGENT;
BIOLOGICAL MARKER;
CANAKINUMAB;
CYTOKINE;
FOLIC ACID;
METHOTREXATE;
MONOCLONAL ANTIBODY;
FEMALE;
GENE EXPRESSION REGULATION;
GENETICS;
HUMAN;
INFLAMMATION;
MALE;
METABOLISM;
PATHOLOGY;
PHYSIOLOGY;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
THROMBOSIS;
ANTI-INFLAMMATORY AGENTS;
ANTIBODIES, MONOCLONAL;
BIOLOGICAL MARKERS;
CYTOKINES;
FEMALE;
FOLIC ACID;
GENE EXPRESSION REGULATION;
HUMANS;
INFLAMMATION;
MALE;
METHOTREXATE;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
THROMBOSIS;
|
|
EID: 84895856313
PISSN: 00657778
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (69)
|
|
References (0)
|
